CDC Updates Hepatitis B Vaccine Guidance: Individual Choice for Infants
Atlanta, December 16, 2025 – The Centers for Disease Control and Prevention (CDC) has shifted to an individual-based approach for hepatitis B immunization decisions, specifically for infants born to mothers who have tested negative for the virus. This change, approved by the CDC’s Acting Director and Deputy Secretary of Health and Human Services Jim O’Neill, allows parents, in consultation with their healthcare providers, to determine the timing of their child’s hepatitis B vaccine series, including whether to administer the birth dose.
For infants not receiving the initial dose at birth, the CDC suggests the first vaccine dose be given no earlier than two months of age. This represents a move toward “shared clinical decision-making,” where the benefits and risks of vaccination are weighed against the individual infant’s potential exposure risk. Factors considered should include household contacts with hepatitis B or frequent interaction with individuals from regions where the virus is prevalent.
Understanding Hepatitis B and Vaccination
Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. The CDC emphasizes that the hepatitis B vaccine is both safe and effective, providing long-term protection. Although, the risk of infection for newborns born to mothers who do not have the virus is considered low, prompting the reevaluation of the universal birth dose policy.
The current standard of care for infants born to mothers who test positive for hepatitis B, or whose status is unknown, remains unchanged: they continue to receive the birth dose of the vaccine and hepatitis B immunoglobulin (HBIG) to provide immediate protection.
The Shift to Individualized Decision-Making
This novel guidance stems from a rigorous review by the Advisory Committee on Immunization Practices (ACIP). According to O’Neill, the change “restores the balance of informed consent to parents whose newborns face little risk of contracting hepatitis B.” The CDC is also reviewing recommendations regarding serology testing to determine if a subsequent vaccine dose is needed, further emphasizing a personalized approach.
Individual-based decision-making doesn’t mean abandoning vaccination. It means a more nuanced conversation between parents and their doctors, taking into account specific circumstances. This approach acknowledges that a one-size-fits-all strategy may not be optimal for all infants.
What Does This Mean for Parents?
Parents should discuss the potential benefits and risks of the hepatitis B vaccine with their pediatrician or healthcare provider. This conversation should include a review of the family’s risk factors, such as potential exposure to the virus through household members or travel. The CDC’s fact sheet on hepatitis B immunization provides additional information for parents and caregivers.
It’s important to understand that delaying the birth dose doesn’t mean foregoing vaccination altogether. The CDC recommends that all infants eventually complete the hepatitis B vaccine series, regardless of whether they receive the birth dose. The vaccine is typically administered as a series of two or three shots, depending on the vaccine brand.
The Role of Risk Assessment
The CDC’s guidance highlights the importance of assessing individual risk. Whereas the overall risk of hepatitis B infection in the United States is relatively low, certain populations are at higher risk. These include individuals who inject drugs, men who have sex with men, and people who have traveled to regions with high rates of hepatitis B. The CDC’s guidance for healthcare professionals outlines specific recommendations for vaccination based on risk factors.
Understanding the difference between relative and absolute risk is crucial. While delaying the birth dose may slightly increase the absolute risk of infection during the first few months of life, this risk remains particularly small for most infants born to hepatitis B-negative mothers.
Implications for Public Health Programs
The CDC assures that this shift to individual-based decision-making will not disrupt coverage through existing programs like the Vaccines for Children Program, the Children’s Health Insurance Program, Medicaid, and Medicare. These programs will continue to provide access to the hepatitis B vaccine for eligible children.
What to Expect Moving Forward
The CDC will update the child immunization schedule and clinical guidance to reflect these new recommendations. This process ensures that healthcare providers have the most up-to-date information to guide their conversations with parents. The agency will also continue to monitor the impact of this change on hepatitis B vaccination rates and infection rates.
Ongoing surveillance and data analysis will be critical to assess the effectiveness of this new approach and to identify any potential unintended consequences. The CDC remains committed to protecting the public from hepatitis B through evidence-based vaccination strategies.